Title: SOLD ORAL DOSAGE FORMS OF VALSARTAN

Abstract: The present invention is concerned with solid oral dosage forms comprising of a) an active agent selected from valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/41 A61K9/16 A61K9/20 A61K31/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-/-</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

X

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

*"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*"B" document member of the same patent family

Date of the actual completion of the international search

13 January 1998

Date of mailing of the international search report

30.01.98

Authorized officer

Boulois, D

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
| X        | CHEMICAL ABSTRACTS, vol. 124, no. 17, 22 April 1996  
Columbus, Ohio, US;  
abstract no. 220073,  
FUJIMURA Y. ET AL: "Antihypertensive  
effect of a combination of valsartan and  
hydrochlorothiazide, nifedipine or  
propranolol in spontaneously hypertensive  
rats"  
XP002051904  
see abstract  
& FUJIMURA Y. ET AL: "Antihypertensive  
effect of a combination of valsartan and  
hydrochlorothiazide, nifedipine or  
propranolol in spontaneously hypertensive  
rats"  
YAKURI TO CHIRYO,  
vol. 23, no. 12, 1995,  
pages 3241-3247,  
--- | 8-17,27 |
| A        | GRUN A. ET AL: "A comparison of the  
efficacy and toleability of a new  
angiotensin II antagonist, valsartan, with  
enlapril in patients with mild to moderate  
esential hypertension"  
EUROPEAN HEART JOURNAL,  
vol. 16, no. Sup, 1995,  
page 61 XP002051902  
see the whole document  
--- | 1-27 |
| A        | WO 95 24901 A (CIBA GEIGY AG) 21 September  
1995  
see page 6; example 1  
--- | 1-27 |
| T        | MARKHAM A. ET AL: "Valsartan: a review of  
its pharmacology and therapeutic use in  
esential hypertension"  
DRUGS,  
vol. 54, no. 2, August 1997,  
pages 299-311, XP002051903  
see the whole document  
----- | 1-27 |
### Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

   see FURTHER INFORMATION sheet PCT/ISA/210

2.  
Clubs Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.  
Clubs Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2.  
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  

4.  
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.
Remark: Although claim 27 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 9524901 A</td>
<td>21-09-95</td>
<td>AU 1850695 A</td>
<td>03-10-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2184712 A</td>
<td>21-09-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1143908 A</td>
<td>26-02-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 9602688 A</td>
<td>12-03-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0750500 A</td>
<td>02-01-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 963611 A</td>
<td>13-09-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 76542 A</td>
<td>29-09-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9510225 T</td>
<td>14-10-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 963869 A</td>
<td>16-09-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 316259 A</td>
<td>06-01-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 117996 A</td>
<td>05-03-97</td>
</tr>
</tbody>
</table>